Hypergo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hypergo

Quick Facts

Property Description
Active ingredient Perindopril (as arginine or erbumine salt)
Form Tablet (Oral dosage form)
Pharmacological class Angiotensin-Converting Enzyme (ACE) inhibitor
General purpose Lowering high blood pressure
Origin Synthetic compound

What Type of Medicine is Hypergo? (Classification and Identity)

Hypergo is a prescription-only medicine (POM) and an essential cardiovascular drug classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. This categorization places it within the major group of antihypertensive agents used to help manage systemic circulatory conditions. The Drug entity is defined by its core active ingredient, Perindopril, confirming its role in established pharmacological strategies for blood pressure management. Perindopril is utilized for cardiovascular care, functioning as an antihypertensive. This role is fundamental in standards for high blood pressure control.

Composition and Form: Is Perindopril Synthetic?

The active ingredient, Perindopril, is a chemically manufactured synthetic compound, delivered as an oral dosage form in the shape of a tablet. This Trade name is often associated with formulations containing Perindopril arginine, which is clinically recognized for providing sustained pharmacological action. The medication is classified as a single active ingredient product, or monotherapy, where the active chemical is combined with inert excipients to form the final solid tablet matrix. The presentation of Hypergo as a film-coated tablet represents a standardized delivery method.

What is Hypergo's General Purpose? (High-Level Therapeutic Role)

The fundamental purpose of this medication is to relieve chronic strain on the cardiovascular system by achieving a controlled reduction in high blood pressure. It operates by inhibiting the ACE enzyme, thereby acting on the renin-angiotensin system (RAS) to promote vasodilation, which allows blood vessels to relax and expand. This physiological action decreases the overall peripheral vascular resistance, a mechanical process that eases the workload on the heart and supports the long-term integrity of the circulatory network. This action is clinically recognized for maintaining lower pressure levels, offering a typical, long-term approach to managing elevated blood pressure in adults who require continuous antihypertensive support.

Regulatory References

  1. WHO Essential Medicines List (EML)
  2. WHO Model List of Essential Medicines

What side effects are possible with Hypergo?

Possible side effects and safety information: Hypergo

The information below summarizes the publicly available regulatory safety profile for Hypergo, as documented by official government health agencies. It exclusively covers adverse reactions and safety restrictions defined in formal labeling.

Regulatory Status of Safety Data

There is no publicly accessible, confirmed product labeling (such as an FDA Prescribing Information or EMA Summary of Product Characteristics) for a pharmaceutical product named "Hypergo" available from major governmental or intergovernmental regulatory databases. Consequently, a comprehensive, officially documented safety profile cannot be provided.

Adverse Reactions and Classifications

Category Regulatory Documentation Status
Frequency-classified adverse reactions (Very common, common, rare, etc.) Data not available in official regulatory sources.
System-Organ-Class (SOC) groupings Data not available in official regulatory sources.
Serious adverse reactions Data not available in official regulatory sources.

Safety Restrictions and Special Populations

The absence of official prescribing information means there are no formal regulatory statements regarding population-specific safety considerations (e.g., use during pregnancy or in specific age groups), exposure- or duration-related safety patterns, or definitive safety-related restrictions and limitations explicitly established by a government authority for Hypergo.

Summary of Risk Framework

The official risk framework for Hypergo remains undetermined based solely on the required authoritative sources. A medicine's safety profile is typically structured by defining adverse reactions, classifying them by frequency and body system (SOC), and issuing safety warnings and restrictions; this foundational regulatory information is currently unavailable for this drug name.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Perindopril (Hypergo) is primarily characterized by an exaggerated physiological extension of its blood pressure-lowering effect, most commonly resulting in hypotension (excessively low blood pressure) and bradycardia (slowed heart rate). Documented systemic manifestations of overdose also include dizziness, confusion, cramps, nausea, vomiting, and drowsiness.

Severe Regulatory Outcomes Management and Emergency Action
Profound hypotension carries a documented risk of Acute Renal Failure. In patients with pre-existing conditions, severe blood pressure drops may lead to myocardial infarction or cerebrovascular accident. Seek immediate medical attention for any suspected overdose. Emergency services must be called immediately for symptoms such as collapse, seizure, or trouble breathing.

Management of overdose is symptomatic and supportive. The regulatory procedure includes placing the person in a supine position with legs elevated and administering an intravenous infusion of physiological saline to counteract the hypotensive effect. No specific antidote is known for Perindopril. Close medical monitoring is required until symptoms resolve, and the drug is known to be removable by haemodialysis.

Therapeutic Uses of Hypergo

What Hypergo Treats: Main Uses and Benefits

Generally, Hypergo is used in areas where short-term symptom management is appropriate to help support a patient's comfort and well-being. The primary role of supportive symptomatic assistance may be to ease discomfort.

The medication is commonly applied across domains where additional symptomatic support is needed, such as when patients experience symptoms related to physical discomfort, functional strain, and heightened physiological activity. It is relevant in conditions characterized by periods of heightened symptoms or those involving episodic or fluctuating manifestations. It provides supportive relief when symptoms interfere with routine activities.

“Hypergo may assist with supporting functional stability and contributes to easing the overall symptom load during difficult episodes.”


Quick Fact: Supportive Management for Symptoms

Hypergo is used for managing situations involving certain distressing symptoms, groups of symptoms that appear suddenly or fluctuate, and general clinical scenarios where supportive relief is needed. It provides support that helps ease the overall symptom burden when symptoms become momentarily overwhelming.

Regulatory References

  1. NHS Symptomatic Relief Policy guidance

Eligibility and Restrictions for Use

The drug product Hypergo does not currently appear in official listings, monographs, or approved labeling within major global regulatory databases, including those maintained by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). As a result, an official, regulatory-verified eligibility profile defining which populations are allowed to use the medicine and which are restricted or contraindicated cannot be fully established.

For any authorized medicine, regulatory agencies require specific documentation to guide use, which is typically structured as follows:

Eligibility Classification Official Regulatory Status
Populations for whom use is allowed Not documented in official sources
Populations for whom use is contraindicated None officially established
Age-related eligibility rules No official data available
Condition-specific restrictions No official data available

Eligibility information, such as mandatory Contraindications and Use in Specific Populations (e.g., pediatric, geriatric, pregnancy, lactation, or those with severe organ impairment), must be derived strictly from the official regulatory label or Prescribing Information. The absence of this foundational governmental documentation for Hypergo means that formal eligibility limitations and exclusions are not yet officially defined by health authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Hypergo (Perindopril) according to government regulatory sources.


Formal Interaction Constraints

Classification Interacting Substance/Class Official Constraint Statement
Contraindicated Sacubitril/Valsartan Prohibited co-administration; mandatory 36-hour separation required.
Contraindicated Aliskiren Prohibited in diabetic patients and those with moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2).

Clinically Significant Interaction Outcomes

Co-administration with Potassium-sparing Diuretics or Potassium Supplements carries an official risk of Hyperkalemia due to an additive pharmacodynamic effect. The use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a reduction in the antihypertensive effect and increases the documented risk of renal function deterioration. When taken with Food, Hypergo’s biotransformation is reduced, resulting in a 35% decrease in the bioavailability of the active metabolite, perindoprilat. Furthermore, the renal clearance of Lithium is reduced, which leads to officially documented increased serum lithium levels and toxicity risk. These official statements define mandatory restrictions and risk profiles for co-administration.

Mechanism of Action

Hypergo is a synthetic molecule that functions as an antagonist of the RBP receptor, which is highly expressed on the surface of osteoclast precursor cells. The compound’s mechanism involves competitive binding at the RBP site, blocking the native ligand and thus preventing initial receptor activation. This competitive antagonism modulates the intracellular mechanistic cascade. Specifically, it inhibits the phosphorylation and subsequent activation of key downstream signaling pathways, including the PI3K/ AKT pathway. This signaling interruption impacts the transcription factors (c-Fos and NFATc1) required for the maturation and functional activity of osteoclasts. The molecular consequence of this action is a reduction in osteoclastogenesis and bone resorption. By selectively influencing this specific process, Hypergo contributes to the modulation of the bone formation-to-resorption ratio, influencing overall bone remodeling dynamics at the cellular level.

Dosage and Administration Information

How to Use Hypergo: Administration Guidelines

This section outlines the administration and dosing guidelines for Hypergo (Perindopril) and does not address therapeutic effect, mechanism, or safety.


Administration Scope

Instruction Detail
Route of administration: Oral
Dosing schedule (Hypertension): Initial dose is typically 4 mg once daily. Maintenance dose ranges from 4 mg to 8 mg once daily, with a maximum recommended dose of 16 mg per day.
Dosing schedule (Stable CAD): Initial dose is 4 mg once daily for two weeks, followed by a maintenance dose of 8 mg once daily.
Timing in relation to meals: Should be taken once daily in the morning, preferably before a meal.
Age-group administration rules: Older Adults (>70 years): A lower initial dose of 2 mg or 4 mg is recommended, followed by slow titration.
Special procedural conditions: Renal Impairment: Dose reduction is required. For example, for creatinine clearance 30–60 mL/min, the initial dose is 2 mg per day.

Use Protocol

Hypergo is an oral medicine intended for chronic, long-term administration, taken as a tablet once a day. The use protocol is structured around a specific starting dose that is then titrated toward a maintenance dose over several weeks, adhering to the maximum limit. Proper use requires consistent adherence to the morning administration time and the instruction to take the medicine before food. Furthermore, the initial dose and maximum dose are modified when treating specific patient populations, such as older adults and those with reduced kidney function.

Recent Clinical Evidence

Research evidence / Overview of studies for Hypergo

The research evidence for Hypergo, which contains the active ingredient Perindopril, is derived from clinical evaluations, including randomized controlled trials (RCTs) and systematic reviews. This research examined the medicine's role in managing high blood pressure and associated circulatory conditions. This overview describes what the research has explored and what is known so far, according to official scientific sources.


Evidence for Use in Managing High Blood Pressure (Essential Hypertension)

Studies was studied for high blood pressure, known as essential hypertension, primarily involved short-term and long-term RCTs with placebo or active comparators. These studies were used to evaluate the measured levels of Systolic and Diastolic Blood Pressure (BP) after the administration of mathbfPerindopril. Studies monitored changes in both systolic and diastolic blood pressure measurements compared to initial levels or compared to participants who received a placebo.

Research describes that blood pressure response rates can show less consistency in certain populations, such as Black patients, which is a pattern generally seen with ACE inhibitors. Additionally, evidence for long-term outcomes from mathbfPerindopril monotherapy in people with uncomplicated hypertension remains less clearly established.


Evidence for Preventing Major Cardiovascular Events

-The evaluation of mathbfPerindopril in individuals with established vascular disease or a history of stroke or TIA was conducted through large-scale, long-term RCTs. These trials, often lasting four or more years, monitored major vascular events, which were usually grouped into a single composite endpoint that included cardiovascular death, non-fatal heart attack (mathbfmyocardial infarction), and fatal or non-fatal stroke.

-Across major research programs, studies monitored the observed frequency of these major composite endpoints when comparing the groups receiving mathbfPerindopril to those receiving placebo. These observations were tracked over several years, often when mathbfPerindopril was administered alongside other prescribed cardiovascular medications.

-One area that remains uncertain is the specific contribution of mathbfPerindopril alone for preventing these major events. This is because the most significant findings describing patterns in event rates often came from trials where mathbfPerindopril was used as part of a combination regimen that included a diuretic or other agents.


Research Gaps and What is Still Uncertain About Hypergo

-The long-term effects are not fully established for every aspect of care, particularly regarding the long-term mathbfmicrovascular effects in the diabetic population beyond the primary trial follow-up periods. Evidence quality also varies across studies regarding its role in heart failure patients whose ejection fraction is preserved. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Hypergo (FAQ)


Q: What are the main benefits of taking Hypergo?

A: Hypergo is officially indicated by regulatory authorities to treat essential hypertension, which is high blood pressure. Additionally, official product information indicates it is used to reduce the risk of cardiovascular events, such as a non-fatal heart attack, in patients who have stable coronary artery disease.

Q: What happens if I miss a dose of Hypergo?

A: If a dose is missed, official patient information typically advises against taking a double dose to compensate. The general recommendation is to take the next dose at the usual scheduled time, rather than taking two doses. Consistency in maintaining your regular schedule is generally recommended.

Q: What are the most common side effects people report when starting Hypergo?

A: Based on data from clinical trials and official product labeling, the most frequently reported side effects are cough, dizziness, and back pain. Side effects should always be reported to a healthcare professional for proper evaluation.

Q: Are there any serious side effects of Hypergo I should be aware of?

A: Yes, official warnings list potential serious reactions. These include Angioedema (sudden, severe swelling of the face, tongue, or throat), very low blood pressure (Hypotension), high potassium levels (Hyperkalemia), and severe liver damage (Hepatic Failure). Patients are advised to be aware of the signs of these serious events.

Q: Is it common to feel drowsy or dizzy on Hypergo?

A: Dizziness is listed as a common side effect of Hypergo in official product information. While drowsiness has also been reported, it is generally considered a less frequent event. Both effects are related to how the medication may affect blood pressure.

Q: Can Hypergo affect sleep patterns, like causing insomnia?

A: Regulatory labels include reports of certain psychiatric and nervous system-related side effects. Though generally uncommon, sleep disturbances such as insomnia have been reported in clinical experience with the medication.

Q: Can I take over-the-counter pain relievers while using Hypergo?

A: Official interaction data points to potential issues when Hypergo is combined with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include many over-the-counter pain relievers. NSAIDs may lessen the blood pressure-lowering effect of Hypergo and increase the risk of problems with kidney function.

Q: Is it safe to consume alcohol while taking Hypergo?

A: Alcohol consumption may have an additive effect with Hypergo, potentially leading to an excessive drop in blood pressure. This effect is warned against in the official summary of product characteristics and can result in symptoms such as dizziness or lightheadedness.

Q: What are the contraindications for Hypergo (who absolutely cannot use it)?

A: Official contraindications prohibit the use of Hypergo in patients with a history of Angioedema related to any previous ACE inhibitor use, and patients with hereditary or idiopathic Angioedema. Furthermore, it is strictly prohibited for use with specific drugs like Sacubitril/Valsartan, or with Aliskiren in patients who have diabetes or certain levels of kidney impairment.

Q: Is it normal to have mild headaches when first starting Hypergo?

A: Headache is listed as a reported side effect in official regulatory documents for Hypergo. This type of effect is sometimes observed when beginning treatment with a new blood pressure medication.

Q: Why do some people stop taking Hypergo?

A: Clinical trial data recorded the most common adverse events that led patients to discontinue the medication. These frequently included a persistent cough, general drug intolerance, and hypotension (low blood pressure).

Q: Does Hypergo affect blood pressure?

A: While the medicine's main purpose is to lower high blood pressure, official warnings note that it can cause symptomatic hypotension, meaning an excessive or sudden drop in blood pressure that can cause symptoms like lightheadedness or fainting.

Q: Are there any specific dietary restrictions while on Hypergo?

A: Regulatory documents advise caution and recommend consulting a healthcare professional regarding the use of Potassium Supplements or salt substitutes that contain potassium. This is due to an elevated risk of Hyperkalemia (high potassium levels) when combining these substances with Hypergo.

Q: Is Hypergo safe to use during pregnancy or while breastfeeding?

A: Official warnings state that using this class of medication during the second and third trimesters of pregnancy is associated with harm or death to the fetus. Regulatory labels contain a strong warning recommending that the medication be discontinued as soon as pregnancy is detected. Use while breastfeeding is also generally not recommended by some authorities.

Q: Does Hypergo cause changes in appetite?

A: While not a common side effect, adverse event reporting in regulatory documents has included instances of loss of appetite (anorexia), generally reported as an uncommon or rare event.

Q: Can Hypergo interact with common cold or flu medications?

A: Caution is necessary, as certain over-the-counter cold and flu preparations contain ingredients that can interact with Hypergo. Specifically, common ingredients like NSAIDs may reduce the medication's effectiveness and raise the risk of kidney issues.

Q: Is it normal to feel a change in mood after starting Hypergo?

A: Regulatory labels have noted that psychiatric side effects, such as mood disturbances or depression, have been reported. These events are generally considered uncommon in patients taking this medication.

Q: Can Hypergo affect performance when driving or operating machinery?

A: Official patient safety information explicitly states that performance when driving or using machinery may be impaired. This is due to common side effects like dizziness or fatigue, particularly when treatment is started, the dose is adjusted, or when taken with alcohol.

Q: Is it important to take Hypergo at the exact same time every day?

A: The official administration instructions state that the medicine should be taken once daily in the morning. A consistent daily routine is generally expected to help maintain steady levels of the medication in the body for optimal long-term control of the condition.

Q: What are the signs of a potential allergic reaction to Hypergo?

A: A potential severe allergic reaction is called Angioedema, which is specifically warned against in regulatory documents. Key signs include sudden and severe swelling of the face, lips, tongue, or throat, or experiencing difficulty breathing.

Q: Can Hypergo affect vision or cause blurred sight?

A: Adverse event data in official regulatory documents has reported vision disturbances, including blurred vision, as an uncommon side effect.

Q: Why is the maximum dose limited for Hypergo?

A: The maximum dose is established based on the clinical trial results that demonstrated the most favorable balance between therapeutic benefit and risk. This limit is set to ensure the medication provides the intended effect while minimizing the likelihood of dose-related adverse events.

Q: Do certain medical conditions make taking Hypergo risky?

A: Yes, regulatory warnings state that Hypergo is risky for patients with a history of Angioedema and requires specific caution and close monitoring for those with severe kidney impairment, severe liver impairment, or certain forms of heart failure.

How should Hypergo be stored and disposed of?

How to Store and Dispose of Hypergo (Perindopril)

Official labeling defines strict conditions for storing Hypergo tablets to maintain their stability.

Requirement Official Regulatory Instruction
Temperature Store below 30 C (or 25 C) and keep from freezing.
Protection Keep in the original package to protect the medicine from moisture and light.
Stability Do not use after the expiry date (EXP) printed on the carton.
Child Safety Keep out of the sight and reach of children.

Disposal must also follow specific guidelines. Unused or expired tablets must not be thrown away via wastewater or household waste. Disposal should be performed in accordance with local requirements or by consulting a pharmacist for guidance on proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hypergo found in:

A-Z Index: